The adaptive immune system employs an immensely diverse repertoire of lymphocyte receptors to recognize and neutralize foreign agents. Analyzing the composition of B- and T-cell receptors in vivo can provide insight into diseases and aid the development of biologics and vaccines. Surface display technology can also be used as a complementary or alternative approach to discover antibodies, including both antigen-binding (Fab) and single-chain variable fragments (scFv), targeted against an antigen.
Our suite of immunogenomics services provide next generation sequencing solutions for natural and recombinant antibody populations to achieve high-throughput analysis of diverse populations. Options include physical pairing of the VH/VL or α/β chains of each complex and non-physical pairing inferred through frequency analysis. Find the optimal solution for your project below.
Antibody Discovery Platform |
Method of Pairing Chain Sequences | Sequence Target | Applications | |
Frequency Analysis |
Physical Pairing |
|||
In vivo | Immuno-Profiling | Single-Cell Immuno-Profiling |
B-cell receptors (BCR) T-cell receptors (TCR) |
BCR/TCR repertoire In vivo antibody Hybridoma screening |
In vitro | Short-Read Amplicon Sequencing |
Ultra-Long Amplicon Sequencing |
Antigen-binding Single-chain variable |
In vitro antibody discovery via surface display |
Assay the diversity of clones after bio-panning in surface display experiments. Heavy and light chains, amplified separately, are fully sequenced on the Illumina MiSeq platform. We offer the following NGS services for this approach:
Pair BCR and TCR chains at single-cell resolution using 10x Genomics™ technology.
Analyze clonal diversity after bio-panning via long-read sequencing technology. Heavy and light chains amplified together in a single PCR product are contiguously sequenced using the PacBio Sequel® platform. This approach physically pairs the sequences of the two chains.
The quantity and quality of isolated cells are critical to the performance of functional assays. In this tech note, we discuss the challenges associated with PBMC isolation and offer a robust workflow for PBMC isolation and cryopreservation leading to reproducible, high-quality results.
High-throughput technologies are critical in performing phenotypic profiling for drug discovery applications. In this tech note, Azenta Life Sciences discusses the challenges associated with traditional approaches, such as microarrays and RNA sequencing, and offers an optimized assay to achieve high-quality phenotypic profiling at a reduced cost for rapid drug discovery.